Biotechnology

Lite Strategy

Lite Strategy released FY2026 Q3 earnings on May 13 (EST), actual revenue USD 0, actual EPS USD -0.6634

Lite Strategy released FY2026 9 Months Earnings on May 13 (EST), with actual revenue of USD 0 and EPS of USD -1.611

Lite Strategy sees drop in R&D expenses but higher operational losses

Lite Strategy released FY2026 Semi-Annual Earnings on February 17, 2026 (EST) with actual revenue of USD 0 and EPS of USD -1.0303

Lite Strategy released FY2026 Q2 earnings on February 17, 2026 (EST) with actual revenue of USD 0 and EPS of USD -0.8241

Lite Strategy released FY2026 Q1 earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -0.1234

Lite Strategy released FY2025 Q4 earnings on September 26 (EST), actual revenue USD 0, actual EPS USD -0.4034

Lite Strategy released FY2025 Annual Earnings on September 26 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.393 (forecast USD -6.28)

Lite Strategy Inc. Completes Warrant Exercise Transaction

Lite Strategy released FY2025 9 Months Earnings on May 13 (EST), actual revenue USD 0, actual EPS USD -1.9896

Lite Strategy released FY2025 Q3 earnings on May 13 (EST) with actual revenue of USD 0 and EPS of USD -0.3861

Lite Strategy released FY2024 Q3 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 25 K), actual EPS USD -1.3698 (forecast USD -1.4866)

Lite Strategy released FY2024 9 Months Earnings on May 13 (EST), actual revenue USD 65.3 M, actual EPS USD 5.4305

Lite Strategy released FY2025 Semi-Annual Earnings on February 12 (EST), actual revenue USD 0, actual EPS USD -1.6034

Lite Strategy released FY2025 Q2 earnings on February 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4017 (forecast USD -2.2)

Lite Strategy released FY2024 Semi-Annual Earnings on February 12, 2025 (EST), with actual revenue of USD 65.3 M and EPS of USD 6.8003

Lite Strategy released FY2024 Q2 earnings on February 12 (EST), actual revenue USD 0 (forecast USD 66.67K), actual EPS USD -1.6603

Lite Strategy released FY2025 Q1 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.2017 (forecast USD -1.7)

Lite Strategy released FY2024 Q1 earnings on November 12 (EST), actual revenue USD 65.3 M, actual EPS USD 8.4607

Lite Strategy released FY2023 Annual Earnings on September 19 (EST), actual revenue USD 48.82 M (forecast USD 48.29 M), actual EPS USD -4.7783

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

LTCC

LITS

LTCN

Litecoin is currently consolidating around the $55 mark, with a neutral Relative Strength Index (RSI) of 52.68. Analysts predict a potential upside movement to the range of $61 to $66 by the end of the month based on technical analysis. The crucial resistance level to watch is at $57.43, which could serve as an immediate trigger for further movement.

Unusual Whales

Canary Litecoin ETF

Grayscale Litecoin Trust (LTC)

LTC expected to hit $61-66 by April end; RSI stable at 52.68. $57.43 resistance crucial, indicates technical analysis.

The cryptocurrency Litecoin is currently valued at $53.16 and is experiencing a downward trend. However, there is a possibility of a price recovery to the range of $60-65 if the crucial support level at $50.61 remains unbroken. Analysis based on technical indicators indicates a period of consolidation before any significant price movement occurs.

Litecoin's price at $53.16 with potential to hit $60-65 by March 2026 if $50.61 support holds. Technical analysis indicates consolidation.

Lite Strategy, Inc. reported Q2 fiscal 2026 results, earning $600,000 from a covered call options program and initiating a $25 million stock buyback. The company, the first U.S. public firm to use Litecoin as its primary treasury reserve, aims to enhance shareholder value and support the Litecoin ecosystem through active capital market strategies. CEO Jay File highlighted the shift from merely accumulating LTC to implementing productive financial strategies, which may also help reduce market volatility for investors.

Lite Strategy, Inc. reported Q2 fiscal 2026 results, earning $600,000 from covered call options program and initiating $25 million stock buyback.

Lite Strategy, Inc. (Nasdaq: LITS) reported its fiscal 2026 second quarter results, highlighting a successful deployment of treasury operations and a commitment to leveraging Litecoin holdings. The company generated approximately $600,000 through a covered call options strategy and initiated a $25 million stock repurchase program. With $8.8 million in cash, Lite Strategy aims to differentiate itself from passive investment vehicles by actively managing its digital asset treasury. The company also began pre-clinical research for its drug candidate pipeline, focusing on enhancing shareholder value and supporting the Litecoin ecosystem.

StockTitan

Lite Strategy Reports Fiscal 2026 Second Quarter Results | LITS Stock News

The price of Litecoin has stabilized at $55.44, with technical indicators indicating a possible recovery towards the $65-70 range by March. However, in the short term, bears continue to dominate the market.

LTC price to reach $65-70 by March 2026, stabilizing at $55.44. Bulls may challenge bears in the short term.

Currently, Litecoin is being traded at $59.57, indicating a significant decline as the Relative Strength Index (RSI) stands at 27.54, signaling extreme oversold conditions. Based on technical analysis, experts anticipate Litecoin's price to possibly reach the range of $72-75. Analysts recently have predicted that this price range may be achieved by February.

LTC currently at $59.57, RSI 27.54 signals oversold; Analysts foresee $72-75 range recovery by March 2026.

Litecoin is at a critical juncture, with $63 as the key support level for bulls. A break below this could shift momentum bearish, while holding above maintains a bullish structure. Recent updates indicate a shift from neutral to bullish following a long-term structural break. The nine-year trendline remains crucial, with a monthly close above it confirming the uptrend. Conversely, a close below would signal a historic breakdown. Traders are advised to wait for the monthly close or set strict stop losses due to the risks involved.

NewsBTC

Litecoin Structure Intact, But $63 Remains The Line Bulls Must Defend

AIFF

TRIB

ADVB

In Wednesday's after-market session, several health care stocks experienced notable price changes. Gainers included Imunon (up 8.8%), Trinity Biotech (up 7.84%), and Firefly Neuroscience (up 7.27%). Conversely, Biohaven saw a significant decline of 15.9%, while Lite Strategy and Advanced Biomed fell by 12.24% and 12.0%, respectively. The article was generated by Benzinga's automated content engine and reviewed by an editor.

Lite Strategy(LITS.US)